Zenas BioPharma Eyes US IPO Amid Investor Optimism
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO as market hopes for rate cuts and reduced volatility rise.
- Latest
- Trending
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO as market hopes for rate cuts and reduced volatility rise.
Viatris Inc. reports $3.8B in Q2 revenue, boosts 2024 outlook with innovative pipeline progress and strategic investments.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
"Discover 7 breakthrough biotech stocks poised to boost your portfolio in a sector projected to reach $521.6B by 2033. Learn ...
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
Adicet Bio receives an upgrade from Jones Trading, raising its rating to Buy with a new price target of $6.00. ...
Taiho Ventures increases investment pool to $400M, reinforcing commitment to supporting innovative biotech start-ups in drug discovery. #Taiho #biotech #innovation
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.